Cited by 437COVID-19 Clinical Research StudiesLong-Term Effects of COVID-19Dermatological and COVID-19 studies

AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19

Open access
Sultan, Shahnaz, Altayar, Osama, Siddique, Shazia M., Davitkov, Perica, Feuerstein, Joseph D., Lim, Joseph K., Falck-Ytter, Yngve, El-Serag, Hashem B.·2020·Gastroenterology

Abstract

Background & aims Multiple gastrointestinal (GI) symptoms, including diarrhea, nausea/vomiting, and abdominal pain, as well as liver enzyme abnormalities, have been variably reported in patients with coronavirus disease 2019 (COVID-19). This document provides best practice statements and recommendations for consultative management based on a systematic review and meta-analysis of international data on GI and liver manifestations of COVID-19.Methods We performed a systematic literature search to identify published and unpublished studies using OVID Medline and preprint servers (medRxiv, LitCovid, and SSRN) up until April 5, 2020; major journal sites were monitored for US publications until April 19, 2020. We pooled the prevalence of diarrhea, nausea, vomiting, and abdominal pain, as well as liver function tests abnormalities, using a fixed-effect model and assessed the certainty of evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) framework.Results We identified 118 studies and used a hierarchal study selection process to identify unique cohorts. We performed a meta-analysis of 47 studies including 10,890 unique patients. Pooled prevalence estimates of GI symptoms were as follows: diarrhea 7.7% (95% confidence interval [CI], 7.2%-8.2%), nausea/vomiting 7.8% (95% CI, 7.1%-8.5%), and abdominal pain 2.7% (95% CI, 2.0%-3.4%). Most studies reported on hospitalized patients. The pooled prevalence estimates of elevated liver abnormalities were as follows: aspartate transaminase 15.0% (95% CI, 13.6%-16.5%) and alanine transaminase 15.0% (95% CI, 13.6%-16.4%). When we compared studies from China to studies from other countries in subgroup analyses, diarrhea, nausea/vomiting, and liver abnormalities were more prevalent outside of China, with diarrhea reported in 18.3% (95% CI, 16.6%-20.1%). Isolated GI symptoms were reported rarely. We also summarized the Gl and liver adverse effects of the most commonly utilized medications for COVID-19.Conclusions GI symptoms are associated with COVID-19 in <10% of patients. In studies outside of China, estimates are higher. Further studies are needed with standardized GI symptoms questionnaires and liver function test checks on admission to better quantify and qualify the association of these symptoms with COVID-19. Based on findings from our meta-analysis, we provide several Best Practice Statements for the consultative management of COVID-19.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2020.05.001

Cites

113 of 113 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

1 retracted

Flagged first, then by citations

Research works printed but not linked: 3

  1. [64]Gritti G. Raimondi F. Ripamonti D. Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory support medRxiv 2020 2020.04.01.20048561
  2. [109]Cai Q, Yang M, Liu D, et al. Experimental treatment with Favipiravir for COVID-19: an open-label control study. Engineering (Beijing) 2020. 10.1016/j.eng.2020.03.007. Online ahead of print. PMC7185795 32346491 · DOI
  3. [111]National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD); 2012. Lopinavir. [Updated 2017 Sep 1]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547961/. Accessed April 27, 2020.

Cited by

Sorted by citations

Authors
Sultan, S., Altayar, O., Siddique, S. M., Davitkov, P., Feuerstein, J. D., Lim, J. K., Falck-Ytter, Y., & El-Serag, H. B.
Affiliations
  • University of Minnesota (US)
  • Washington University in St. Louis (US)
  • University of Pennsylvania (US)
  • VA Northeast Ohio Healthcare System (US)
  • Beth Israel Deaconess Medical Center (US)
  • Yale University (US)
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2020-07
Volume
159
Issue
1
Pages
320-334.e27
ISSN
0016-5085 (ISSN-L)
OpenAlex
W3022504328
Cited by
437
References
113
Citations by year
2026: 12 · 2025: 16 · 2024: 15 · 2023: 54 · 2022: 107 · 2021: 142 · 2020: 90
FWCI
4.64
Type
journal article
Language
en
Open access
Locations
  • Gastroenterology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Scholarly Commons @ Case Western Reserve University (submittedVersion)
Funders
  • National Institutes of Health (UL1TR001863)
  • National Center for Advancing Translational Sciences
Topics
  • Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
  • Health Sciences › Medicine › Neurology › Long-Term Effects of COVID-19
  • Health Sciences › Medicine › Dermatology › Dermatological and COVID-19 studies
Keywords
COVID-19 pandemic, gastrointestinal manifestations, diarrhea, nausea and vomiting, abdominal pain, liver enzyme abnormalities, aspartate aminotransferase, alanine aminotransferase, prevalence, hospitalized patients, adverse drug reactions, best practice recommendations
MeSH terms
Betacoronavirus, COVID-19, SARS-CoV-2, COVID-19 Testing, Antiviral Agents, Gastroenterology, Gastrointestinal Diseases, Humans, Liver, Liver Diseases, Liver Function Tests, Pneumonia, Viral, Referral and Consultation, Societies, Medical, United States, Prevalence, Practice Guidelines as Topic, Coronavirus Infections, Clinical Laboratory Techniques, Gastrointestinal Tract, Pandemics

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review